Image source: Getty Images.
Continue Reading Below
Celldex Therapeutics (NASDAQ: CLDX) closed up 11% Tuesday without any obvious news to support the double-digit gain.
As often happens, investors may be piling into Celldex on Tuesday ahead of expected data from a phase 2 clinical trial testing the biotech's lead drug, glembatumumab vedotin, in melanoma patients. The data will be presented at the European Society for Medical Oncology (ESMO), which starts on Oct. 7.
Some of the ESMO abstracts are scheduled to be released Wednesday at 6:00 a.m. EDT, so Tuesday's bounce could be from last-minute investors hoping that the data in the abstract will cause an even bigger bounce on Wednesday.
Keep in mind that abstracts for the meeting were due in May, so Celldex's abstract won't have the most up-to-date data -- the study only completed enrollment in April -- and investors will have to wait for the meeting to get a complete picture of how glembatumumab vedotin performed. And if Celldex Therapeutics was given an oral presentation spot, the abstract won't be released until Oct. 5.
What we do know is that the clinical trial was deemed successful -- defined as at least six responses in the first 52 treated patients -- which Thomas Davis, Celldex's chief medical officer, said was "met and exceeded."
Exceeded by how much is really the key question. These are melanoma patients that have failed other treatments, so a substantially high response rate could be enough to get the drug an accelerated approval or, at the very least, give investors confidence that the drug is working. Celldex is also testing glembatumumab vedotin in combination with one of its other drugs, varlilumab, in melanoma patientsand in a separate study in patients with metastatic triple negative breast cancer.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.